I recently interviewed Bob Langer–MIT biotech guru extraordinaire–on behalf of the EBD Group, which holds international partnering conferences for the life sciences six times a year.  Here’s the opening…and a link to the rest, on the EBD Site. The piece will also  appear in xconomy shortly. Full disclosure…Bob is a personal friend, former classmate, and a member of the Harris Communications Group advisory board…so this should be considered a sponsored post.

–Anita M. Harris

When Bob Langer joined the MIT faculty in 1977 he had a rocky start. Trained as a chemical engineer and working on drug delivery systems, many of his ideas went against conventional wisdom. “I had people write the most insulting things about my knowledge of biology and medicine. Many thought my ideas were crazy. A number of professors wanted me to leave and my first nine grant proposals were turned down.”

Eventually, after numerous academic scientists and companies repeated and used his work Langer was able to get grant funding from the NIH. He also turned to companies for research funding—in return for licensing his patents—which, at that time, also went against the conventional grain.

Today, Langer is one of 13 Institute Professors (being an Institute Professor is MIT’s highest honor) at Massachusetts Institute of Technology. With more than 1,400 articles to his credit, he is the ninth most cited individual in history, according to Google scholar. (Sigmund Freud is first). His 1,300 patents, licensed or sublicensed to more than 350 companies in pharmaceutical, chemical, biotechnology and medical device fields, have led to more than 100 products currently in use or in clinical trials. He has received more than 220 major professional awards including the Queen Elizabeth Prize for Engineering, Priestly Medal, National Medal of Science, National Medal of Technology and Innovation, the Charles Stark Draper Prize (considered the equivalent of the Nobel Prize for engineers), and the Lemelson-MIT prize for being “one of history’s most prolific inventors in medicine.” In June 2018, he was named a US international envoy for science by the US State Department.

Despite his success, Langer remains well aware of his early setbacks, and, as a scientific advisor to some 200 companies over the past 40 years, is highly cognizant of what can go wrong.

“You can have bad animal results, failed trials, or patent problems. I’ve seen partners pull out, companies take bad loans, and the FDA create delays. Stumbling blocks can arise anywhere along the way,” he says.

One of the most difficult problems can occur early on “when a researcher has good findings but is not far enough along for investors or companies to want to spend a lot of money.” In that situation, known as “the valley of death,” Langer says, “the question is how to get enough data so that will change.”

More: 

Anita M. Harris is a writer and communications consultant based in Cambridge, MA.

New Cambridge Observer is a publication of the Harris Communications Group, also in Cambridge.

Spent an interesting Wednesday afternoon, last week,  visiting exhibitors at the Bio-IT World Conference & Expo –several of whom won “Best of Show” Awards later that day.

The judges, listed below,  named winners in six categories: Data Integration & Management; Analysis & Data Computing; Genomic Data Services; Data Visualization & Exploration; Storage Infrastructure & Hardware; and the Judges’ Prize.  Attendees also voted on the People’s Choice Award, selecting products that they believed measurably improve workflow or capacity, enabling better research.

One of my favorites was Nanome, which won best in show for Data Visualization and Exploration.
Nanome uses virtual reality to improve the drug discovery process, according to its award application. The company offers applications for experimentation, collaborattion, and learning at the nano-scale– leveraging  VR hardware such as the Oculus Rift and HTC Vive to create immersive virtual workspaces allowing users to visualize, design, and simulate molecules, proteins, and more.

At  Nanom’se i BIO–IT World booth, Marketing Director Jarrell James handed me a pair of VR goggles and two joysticks (?) with which  I could explore within a molecule–by seeming to make components larger, smaller or revolve.

A more sophisticated user might be able to:

• -Import molecular structures from a local machine or an online database such as RCSB or DrugBank.
• – Manipulate molecular structures by literally grabbing, rotating, or enlarging the area of interest with their hands.
• – Apply different representations to their selection of Atoms, Residues, Chains, or Proteins such as Stick, Wire, Ball & Stick, or Van der Waals.
• – Measure distances and angles between atoms.
• – Mutate amino acids and cycle through rotamer libraries.
• – Design small molecules by building with any element from the periodic table.
• – Minimize manipulated molecules to prevent clashes and provide a local energy minimum conformation.
• – Duplicate or Split any selected area of your structure to modify or export independently.
• – Export your molecular structures to PDB.
• – Join a virtual reality session as a guest with or without virtual reality hardware.

• – Present and collaborate in the same virtual environment with colleagues to demonstrate proposals or compare before and after results.

Nanome plans next to enter the education space. The company’s VR technology wil help high school and college students , likely already proficient in gaming technology,  better understqand biologic processes, James said.

The Hyve 

I also spent some time with the folks at Hyve…whose fake robot ( that is, a “robot inhabited” by a human) did make me  curious about Hyve’s work.

RADAR-base
radar-cns.org

As described in the company’s award submission,  the company’s RADAR-base, developed in the framework of the IMI RADAR-CNS project, is an open source platform designed to securely collect, store and share readings from wearable devices and smartphone sensors to enable remote monitoring. The RADAR-base platform consists of three major categories of components:

• Data ingestion: Recognizing and registering data-sources (including smartphones and wearable devices), collecting the data via a direct Bluetooth connection or through a 3rd party API and streaming in near real time to the server (green box in the figure). Using Apache Kafka, the collected data is streamed to dedicated topics in real-time where the data is optimally schematized using Apache Avro;
• Data storage and management: Consists of two centralized storage systems behind an authorized security layer. A cold-storage based on HDFS that is scalable and fault-tolerant focusing on storing large volumes of high frequency raw-data, and a hot-storage based on MongoDB storing aggregated data to provide a near real-time overview of the raw-data. (blue box in the figure);
• Data sharing: Visualizing aggregated data in a live dashboard and exporting raw data for further analyses in various formats including AVRO, JSON and CSV (yellow box in the figure).

The platform is highly secured by a centralized management system of users and their authorities, participants, allowed devices and their specifications. RADAR-Base platform is distributed as Docker containers with associated scripts and configuration files to enable easy installation.

 In addition, I  visited Sinequa, which took the prize in the Analysis & Data Computing category. 

Sinequa ES v10
sinequa.com

The Sinequa Cognitive Search and Analytics platform handles all structured and unstructured data sources and uses Natural Language Processing (NLP), statistical analysis and Machine Learning (ML) in order to create an enriched “Logical Data Warehouse” (LDW). This LDW is optimized for performance in delivering rapid responses to users’ information needs. Users can ask questions in their native language or ask that relevant information be “pushed” to them in a timely fashion when it emerges.

More than 180 connectors ready for use “out of the box” make the process of connecting multiple data sources fast and seamless. Company and industry-specific dictionaries and ontologies can be easily integrated, putting specific knowledge “under the hood” of the Sinequa platform, making it an intelligent partner for anyone in search of relevant subject information.

Other awards, as descrbed in company literature: :

Genomic Data Services

Diploid
Moon 1.0
diploid.com/moon

Moon is the first software to autonomously diagnose rare diseases from WES/WGS data. By applying AI to the domain of rare disease diagnostics, Moon brings speed and scalability to the genome interpretation process.

The software only requires the patient’s gender, age of onset and his/her symptoms – in addition to the genetic data. Moon then goes from whole genome variant data (VCF) to pinpointing the causal variant in less than 5 minutes.

The software highlights one or a few variants that could explain the patient’s phenotype. For every variant, Moon displays an extensive list of annotations that it mined from the literature, allowing geneticists to easily verify decisions from the AI algorithms. Moon’s speed does not only save a lot of time and money, it also saves lives: Moon has already proven its utility in the NICU at Rady Children’s Hospital (San Diego): https://goo.gl/7TDrQD.

Unfortunately, about 50% of rare disease patients remain undiagnosed, even after whole genome sequencing and expert interpretation. Most hospitals don’t have the resources to keep analyzing negative cases even though new correlations between genes and disorders are published every day. Moon changes all this: as the software autonomously mines the literature and analyses samples, it can reanalyze older, negative cases in the background. Only when new information that might lead to a diagnosis becomes available, the assigned geneticist is notified. That way, hospitals can frequently reanalyze thousands of cases with minimal labor, providing a perspective to undiagnosed patients.

Storage Infrastructure & Hardware

PetaGene
PetaSuite Cloud Edition – Version 1.2
petagene.com

Launching at Bio-IT World 2018, PetaSuite Cloud Edition (CE) combines two innovations: (i) the ability for a user’s software tools and pipelines to seamlessly integrate with a wide variety of cloud platforms without modification, and (ii) significantly improved, high-performance, scalable PetaSuite genomic compression technology. 

For example, users can now directly run, without modification, their custom BWA-mem, GATK, Python, Java, shell scripts, and other POSIX-based software/pipelines streaming directly to/from AWS, Google Cloud, Azure, and private cloud storage, as though they were local filestores. PetaSuite CE supports each platform’s object encryption during transfer and at rest. User applications can connect to multiple cloud platforms, buckets and regions as desired, transparently, and on demand, in user-mode, without needing to modify their pipelines, setup mounts, or have administrator privileges.

Whether running on bare-metal, in VMs, or within Docker containers, for public, private or hybrid cloud, PetaSuite CE enables organizations to unlock the power of distributed object storage seamlessly from their POSIX-compliant tools and pipelines.

PetaSuite CE is built from the ground-up for the extremely high performance streaming and random-access workloads demanded by genomics applications. The integrated, transparent PetaGene compression has been significantly improved to deliver even faster compression and greater reductions of up to 6x of both BAM and FASTQ.GZ files, enabling large costs savings in cloud storage and data transfer times. Moreover, PetaGene compression can also preserve the MD5 checksum of the original BAM or FASTQ.GZ file and not just the internal raw SAM/FASTQ data.

The Judges’ Prize went to 

 Linguamatics and its iScite 2.0 (iscite.com) provide a Software-as-a-Service search application that puts the power of text analytics directly into scientists’ hands, according to the company writeup.

Using Linguamatics’ Award-winning Natural Language Processing
Researchers can extract and analyze relevant data to rapidly answer business-critical questions. iScite utilizes Linguamatics’ award-winning Natural Language  L(NLP) based blend of analytical methods. By understanding the semantics and structure of text, iScite handles the variety of ways people express the same information, ensuring searches are comprehensive and accurate.

Easy to use on any device
iScite’s intuitive HTML interface includes a simple search box and auto-complete suggestions. The innovative answer-routing engine lets users answer simple or complex questions using puzzle-piece building blocks – simplifying access to powerful queries that extract concepts, relationships, numerical data such as drug dosages, mutations and more.

Get answers to questions, not just documents
Data sources include Linguamatics’ cloud-hosted content. MEDLINE, Clinical Trials.gov, FDA Drug Labels, PubMed Central, and Patent Abstracts are annotated with curated terminologies for diseases, drugs, genes and organizations. Scientists can answer questions such as:

• What genes are involved in breast cancer?
• What protocol designs have been used for immuno-oncology trials?
• What are the adverse events for kinase inhibitors?

Actionable results
Results are presented in structured form, with bar chart facets for dynamic, visual results-filtering, a document viewer that highlights key terms and relationships, and relevant link-outs. Users can curate, save, and export their results.

iScite allows users across drug discovery and development to cut through the vast information landscape and discover the most valuable insights.

The People’s Choice award went to 

OnRamp BioInformatics, Inc. and itsROSALIND™ platform:  the first-ever genomics analysis platform specifically designed for life science researchers to  analyze and interpret datasets, while freeing up more time for bioinformaticians.

Named in honor of pioneering researcher Rosalind Franklin, who made a major contribution to the discovery of the double-helix structure of DNA with her famous photograph 51, OnRamp’s ROSALIND platform aims to simplify the practice of genomic data interpretation. According to the company’s writeup,  ROSALIND puts the researcher into the driver’s seat of data analysis and democratizes bioinformatics by broadly expanding access to genomic and proteomic technologies for cancer research, precision medicine and sustainable agriculture.

While many open-source tools remain the lifeline of genomic analysis, a simplified and innovative user experience for the biologist can empower them to run their own analyses, while utilizing these tools without the need for typing any command-line instructions.

ROSALIND is powered in partnership with Google Cloud and features scalable compute power and economical cloud-based storage. ROSALIND is a swarming docker-based genomic analysis solution incorporating the industry’s most trusted open-source tools and algorithms, with an angular front-end and secure RESTful API. ROSALIND is also deployable on-premise.

On Ramp technololgists believe that empowering biologists with “an intuitive and comprehensive platform” to explore their data and collaborate with colleagues and bioinformaticians, they  can help accelerate their industry and the widespread adoption of genomic technologies by dramatically lowering costs, reducing  complexity and, ultimately, focus more on what what to do with results, rather than on how to get to them.

In the words of Allison Profitt, BIO-IT World’s editor,” The awards program recognizes the best of the innovative product solutions for the life sciences industry on display at the conference,

“It’s always a treat to explore what’s new in our industry.

” The innovation on display by Bio-IT World exhibitors never disappoints, and we are excited to shine a spotlight on the best life sciences has to offer.”

Judges
“The Best of Show program relies on a panel of expert judges from academia and industry who screen eligible new products and hear presentations from a list of finalists on site. This year our judges considered 46 new products and viewed presentations on site from 18 finalists.”

The 2018 judging panel included Joe Cerro, BostonCIO; Chris Dwan, Bridgeplate; Richard Holland, New Forest Ventures; Eleanor Howe, Diamond Age Data Science; Phillips Kuhl, Cambridge Healthtech Institute; Steve Marshall, Marshall Data Solutions; Michael Miller, Genentech; Art Morales, Analgesic Solutions; Nanguneri Nirmala, Tufts University School of Medicine; Alexander Sherman, Massachusetts General Hospital; Subi Subramanian, Vertex Pharmaceuticals; Bill Van Etten, BioTeam; and Proffitt.

–Anita M. Harris
Anita Harris is a science writer based in Cambridge, MA. 
New Cambridge Observer is a publication of the Harris Commmunications Group, also in Cambridge, ma.  

Links to
Part I Overview, Watson, analytics
Part II digital devices, long term care.
Part III Apps, devices, roadblocks

Behavioral and Population Health; Roadblocks to change

Can mobile apps really improve mental health? Cut the costs of health care? Help professionals track and care for patients? At a day-long conference sponsored  on health systems innovation organized the MIT/Sloan MIT  Initiative for Health Systems Innovation (HSI), experts from a variety of fields attempted to answer those and other questions aimed at furthering a transformation of  the US healthcare system.  Part III of a series about the conference describes apps and devices for behavioral health, personalized and long-distance care. It also discusses new state models to integrate community, health and social systems aimed at tracking and caring for patients and points out that no matter how sophisticated the technology, it is still up to human beings to make it work.

Behavioral Health

Don Mordecai, Kaiser Permanente

Dan Mordecai, MD, National Leader, Mental Health and Wellness at the managed care consortium Kaiser Permanente described:

• Promising mobile apps aimed at helping people prevent or overcome eating disorders, addiction, or suicide; remain on diets or exercise plans; or connect them with treating providers or coaches.
• Wearables that can measure how much people move or perform text and voice analysis to help professionals understand who needs care, months or years before it is needed.
• Predictive analytics to help prevent self-harm

While many of the above technologies have yet to be proven effective, Mordecai said, telehealth technology has been shown to be helpful in supporting and promoting long-distance health care for areas with shortages of medical personnel.  Telehealth may be carried out through videoconferencing, store-and-forward imaging, streaming media, and terrestrial and wireless communication.  

Mordecai also pointed out that with digital advances, “we are moving from individual doctor patient relationships” to a “personalized’” system, which relies increasingly on data, but that “there is a long way to go.”    Mordecai plans to use what he termed “crowd sourcing” to analyze the effectiveness of apps and other new health technologies, based on the electronic health records of Kaiser Permanente’s   nearly 12 million patients.

State models and population health
Analysis like that used at Kaiser Permanente is crucial for assessing treatment and cutting costs, but it is more challenging to perform outside of managed care programs, which have access to a vast array of patient records, according to Michael Wilkening, the California Undersecretary for Health and Human Services.  Analysis to records for care funded by government or private insurance is hampered by fragmented  social, health provider and  insurance systems and by legal and technical challenges of sharing patient data among those systems,

The New York State Medicaid director, Jason Helgerson, pointed out that for state Medicaid systems,  which serve mainly low-income populations,  it can be difficult to simply keep track of patients,  much less co-ordinate and evaluate their care or reduce their treatment costs.  As an example, he described a city homeless shelter that serves breakfast and dinner, but not lunch. Hungry residents regularly go to the fire station next door and complain of chest pain; they are taken by ambulance to a hospital emergency room, where they are evaluated, at high cost, given lunch, and then transported back to the homeless shelter in time for dinner.

Medicaid systems in at least several states are working on projects to prevent such situations by better integrating social services with medical and behavioral health care. Some are starting to employ analytics to recommend, monitor and measure the success of treatments, and to pay for performance rather than service.  As a result, Helgerson said, “Medicaid may be in the best position to drive change” in health delivery systems.

Roadblocks to change
Still, as a variety of speakers pointed out, despite the promise of digital innovation, there are many roadblocks to change.   Such roadblocks include: reluctance to replace or augment human decision-making with digital solutions;  complex reimbursement systems  and the need for insurer “buy-in” to pay for new technologies;  disparate stakeholders with different goals;  issues of privacy and security;   the  tendency of legislators and other policymakers to view health problems as individual rather than societal;   failure to address the lack of food and shelter that leads to poor health and expensive repeat hospital visits;  and, last but not least, cost.

In the words of Vocera’s Elizabeth Boehm, regarding systemic change, “it takes more than technology to get it done.“

And, as Restef Levi, of the Sloan School, put it: “Technology is important but…at the end of the day, health is about humans.”

LINKS TO:

Part I Overview, Watson, analytics
Part II digital devices, long term care.
Part III Apps, devices, roadblocks

Videotapes and photos of the conference, held November 29, 2017, are available at http://mitsloan.mit.edu/alumni/events/2017-cambridge-health-conference/

–Anita M. Harris

Anita Harris is a writer and communications consultant specializing in health science and technology.

New Cambridge Observer is a publication of the Harris Communications Group, a content and digital marketing firm based in Cambridge, MA.

Much enjoyed last week’s opening of the Koch Institute’s 2017 Image Awards Exhibition. The exhibit, dubbed “with/in/sight”  includes 10 scientific images chosen as best-in-class from among some 120 entries from MIT life scientists and their collaborators across the country–and one from Ireland.

The display, in the public galleries at the Koch Institute for Integrative Cancer Research, is the Koch’s seventh in as many years. Its goal is to celebrate “the diversity of biomedical research at MIT and offers insight into the important role that science and engineering play in our complex and ever-changing world,” according to a Koch brochure.

The images are printed on t-shirt material stretched across frames back lit with LEDs. They are striking artwork in themselves– and showcase some of the most exciting work under way in the cancer research arena.

“Making Waves: Delivery for Ageless Skin.” Koch Institute, Harvard University, Mass General Hospital.

“Making Waves” conveys research on non-invasive sound waves that carry genetic material through protective layers of skin, transferring genes to cells whose genetic clocks have been turned back by the nucleic acids they have received– in order to reverse skin-aging. Credits go to Carl Schoellhammer, Denitsa Milanova, Hamberto Trevino, Cody Cleveland, Jeffrey Wyckoff, Anna Mandinova, Giovanni Traverso, Robert Langer, and George Church.

Whithead Institute: Snap Chat: A Flatworm Creates a New Profile

At the Whitehead Institute, Samuel LoCascio, Kutay Deniz Atabay and Peter Reddien are studying planarian flatworms to learn more about how they regerate. Each color in their image represents a different layer of neurons in the flatworm’s head.

Downstream Dreams: Investigating Melanoma in a Zebrafish: Koch Institute, MIT

Dahlia Perez and Jacqueline A. Lees are studying zebrafish to provide insight into melanoma. This image shows the organization of zebrafish cells in their normal state. Next, biologists will mutate a single gene known to initiate a certain melanoma in order to determine its “downstream” effects.

Center: “Minding the Gap: Studying the Tumor Extracellular Matrix,” Koch Institute

Tumor Penetrating Nanoparticles Infiltrate Cancer Cells, Koch Institute

Steffen RIckelt and Richard Hynes of the Koch Institute are studying not the clusters of brownish colon cancer metasteses shown in the image, screen, but, rather, the “seeming neutral” tissue matrix around them. The goal is determine how the matrix impacts the progression of tumor cells navigating a complex network of cells and proteins.

Langliang Hao, Srivatsan Raghavan, Emilia Pulver, Jeffrey Wyckoff and Sangeeta Bhatia of the Koch Institute are using  biocompatible nanoparticles (yellow) to target and penetrate clusters of cancer cells (pink) with the goal of delivering treatment.

Body of Knowledge: Self-Organized Brain Cells, MIT Department of Biological Engineering and Koch Institute at MIT.

Colin Edington, Iris Lee and Linda Griffith of MIT are involved in the Griffith lab’s “Human on a Chip,” project, in which many different”mini organs”, developed from stem cells in matrix, are linked together in a bioreactor platform. The researchers are studying interactions of multiple organs and the cross between them in order to develop new disease treatments. Shown here are neurons (green) and astrocytes (red).

Microfluidics for the Masses, Measuring Cell Growth Rates, Koch Institute

Selim Olcum, Nathan Cermak and Scott Manalis are using microfluidics to measure the response of cell masses to drugs. Their image shows fluid filled channels (bottom) connected to tiny mass sensors shaped like hollow diving boards (top); the sensors’ whose  vibrations precisely reveal the mass of individual cells passing through them. As treated cells flow across the array of sensors, each cell is weighed multiple times, thereby revealing how quickly the mass of individual cells is changing. Researchers are beginning to use this method to predict optimal treatment strategies for individual patients.

Hashtag No Filter,: Visualizing Breast Cancer Conversations. Royal COllege of Surgeons in Ireland and Wellcome Images.

My favorite image does not show cells, nor was it submitted by an MIT lab. Rather, it visualizes twitter conversations about breast cancer carried out by a network of connected cancer patients and their loved ones, patient advocates, health care professionals, and researchers. The image, by Erie Clarke, Richard Arnett and Jane Burns of the Royal College of Surgeons in Ireland,  represents 92, 915 tweets posted over an eight-week period. It is from the Wellcome Images collection.

Other images not included here display pathways taken by metatastic lung cancer cells over time and  ovarian cancer cells as they break through the abdominal wall.

I’m the first to admit that these photos do not do justice to the real images–nor do they adequately convey the amazing convergent technologies –including imaging–used to carry out the research.

The gallery,  at street level in the Koch Institute, 500 Main Street, in Cambridge, is open to the public at no charge from 8-6 Monday-Thursday, and until 4 pm on Friday. The images are also visible from the sidewalk, outside.

Through March 2018.

Anita Harris is a writer, photographer and communications consultant based in Cambridge, MA.
New Cambridge Observer is a publication of the Harris Communications Group, an award-winning PR and market development firm located in Kendall Square, Cambridge.

Boston area  startups Cocoon Biotech, Riparian Pharmaceuticals, Cellanyx Diagnostics, and DavosPharma  were awarded$22K in funds and in-kind services at an innovation competition held by Biotech Tuesday, a Cambridge-based networking organization for life science professionals.

left-to-right : Execs from EMD Serono, Novartis and Lab Central

At an event on November 19th event, executives from EMD Serono, Novartis Institutes for BioMedical Research and LabCentral chose the winning startup pitches from among five finalists’ presentations. The finalists were selected from an initial field of thirteen online entries based, in part, on online feedback from BiotechTuesday members. The three winners were all therapeutics and diagnostics startups proposing solutions to challenging medical problems.

Cocoon Biotech, Inc., led by CEO and founder Ailis Tweed-Kent, a doctor at Massachusetts General Hospital won the $5000 EMD Serono Innovation Award.  Cocoon Biotech is developing a silk-based gel for injection into the joint to provide long lasting joint support and lubrication in patients with osteoarthritis.  EMD Serono is the biopharmaceutical subsidiary of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical group.

Riparian Pharmaceuticals, led by Will Adam, Chief Scientific Officer and President, won both the $10,000 in-kind Novartis Innovation Award and the $3000 in-kind Pharmatek Innovation Award. Riparian Pharmaceuticals is focused on therapeutics that induce an anti-inflammatory response in cells to address diseases such as atherosclerosis.  Novartis Institutes for BioMedical Research, Inc. discovers and develops new and innovative medicines. Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical & biotechnology industries.

Cellanyx Diagnostics, led by Co-Founder and CEO Ashok Chander, won the $4000 in-kind LabCentral Innovation Award.  Cellanyx is developing a prostate cancer diagnostic based on culturing tumor biopsy cells that promises to be much more accurate than current diagnostics.  LabCentral provides fully functional lab space, permits, waste handling, plus all reasonably common lab equipment for bioresearch.

In addition to awarding startups, the event also acknowledged the contribution of life science products and services in enabling cutting edge research for new therapeutics.  DavosPharma won the Most Innovative Product or Service Award in recognition of its Anthem-GenTox product. This product offers scientists a high throughput genotoxicity assay based on human cells with greatly improved accuracy over conventional methods.

“This was Biotech Tuesday’s first innovation competition–but by no means its last, “said BioTechTuesday Co-Founder Seth Taylor, who organizes BiotechTuesday and served as master of ceremonies for the event.” The feedback from attendees was overwhelmingly in favor of the competition,” Taylor said.  “We look forward to continuing our efforts to engage our broad community of life science professionals in supporting innovators.”

The competition took place at District Hall, a new event space at 75 Northern Avenue in the Boston Seaport District.

–Anita Harris

Anita Harris is a writer and content expert based in Cambridge, MA. 

New Cambridge Observer is published by the Harris Communications Group,  a PR and marketing firm based at the Cambridge Innovation Center, in Kendall Square. HarrisCom offers writing and content services for clients in healthcare, life sciences, biotech, energy and the environment.  Full disclosure:  HarrisCom handled media outreach for the event as a probono sponsor. 

UK-based Alacrita, a global life science consulting firm with consultants worldwide, will soon be opening an office in Cambridge, MA, according to Robert Johnson, who will head the office, here.

The company was co-founded two years ago by Anthony Walker, who had previously served as Executive Director of Global External R&D Europe at Eli Lilly,  and  by Johnson, who had led business development at Onyvax, a biotech company that developed biopharmaceuticals to combat cancer.

Drawing on the capabilities of more than 50 consultants worldwide, Alacrita  provides strategic, operational,  technical  advice or  hands-on project management to organizations of all sizes in  the pharma, biotechnology and life science industries, Johnson said.

According to the Alacrita Web site, clients may be academic institutes, tech transfer experts,  life science investors, startups  or  established companies in need of expertise in:

• Business development and marketing
• Intellectual property
• Product development
• Regulatory affairs

Recent whitepapers available on the  company Website   include:

• Biotech in Israel: A Land of Promise » May 2012 – by Anthony Walker, PhD
• FDA Approvals Provide Reason For Cheer » March 2012 – by Robert Johnson
• Deal Watch Annual Review 2011 » January 2012
• Viewpoint: Pharma Industry Myths » January 2012 – by Anthony Walker, PhD
• Europe’s stellar decade of prostate cancer innovation » September 2011 – by Rob Johnson
• Are we all biotech now? » June 2011 – by Anthony Walker and Rob Johnson
• China: Opportunities for biotech firms » March 2011 – by Rob Johnson and Li Zeng
• Re-Profiling: a Hidden Threat to Originators? » February 2011 – by Dr Jo Davies
• Deal Watch Annual Review 2010 » January 2011 – by Roger Davies and Jill Ogden
• Mitigating Out-sourcing Risk » December 2010 – by Robert Johnson and Anthony Walker
• Deal Watch: a Review of Notable Deals » October 2010 – by Sharon Finch

Alacrita’s US offices will be located in the Cambridge Innovation Center in Kendall Square.  The company name comes from the Latin, “alacritas,” or “lively.”  It is meant to convey “a cheerful readiness,” Johnson said.

–Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.